Tai Tsung Announces Board Approval of Exclusive Licensing Agreement with Subsidiary TCM Life Science Inc. for U101
NQ Score
87/100
N1 Content Completeness
10
AI Summary (NQ-processed)
Tai Tsung's board has approved an exclusive licensing agreement with its U.S.-based subsidiary TCM Life Science Inc. for the global development, registration, manufacturing, and commercialization of U101, with a total contract value of USD 750 million.
AI Analysis
Frequently Asked Questions
- Q: What is the total value of the U101 licensing agreement?
- A: The total contract value is USD 750 million, including development and sales milestones.
- Q: What are the conditions for the contract to take effect?
- A: The contract becomes effective upon the subsidiary’s confirmed receipt of external funding or re-licensing income.
- Q: Who is TCM Life Science Inc.?
- A: It is a U.S.-established subsidiary wholly owned by Tai Tsung.
- Q: What is the strategic significance of this transaction?
- A: Optimizing resource allocation and establishing a risk-mitigated global development framework.
- Q: What was the accountant’s opinion on pricing?
- A: Shuo Yi United CPAs issued an opinion confirming the reasonableness of the price.